NCT07128550 - A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

July 30, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

July 31, 2031

Conditions

Viral Hepatitis

Interventions

DRUG

Tobevibart

Tobevibart administered by subcutaneous injection

DRUG

Elebsiran

Elebsiran administered by subcutaneous injection

DRUG

Bulevirtide

Bulevirtide administered by subcutaneous injection

Trial Locations (20)

30625

RECRUITING

Investigative Site, Hanover

31059

RECRUITING

Investigative Site, Toulouse

33604

RECRUITING

Investigative Site, Pessac

35033

RECRUITING

Investigative Site, Rennes

39008

RECRUITING

Investigative Site, Santander

60590

RECRUITING

Investigative Site, Frankfurt am Main

69004

RECRUITING

Investigative Site, Lyon

78150

RECRUITING

Investigative Site, Le Chesnay

87000

RECRUITING

Investigative Site, Limoges

92110

RECRUITING

Investigative Site, Clichy

93009

RECRUITING

Investigative Site, Bobigny

94804

RECRUITING

Investigative Site, Villejuif

200073

RECRUITING

Investigative Site, Craiova

021105

RECRUITING

Investigative Site, Bucharest

022328

RECRUITING

Investigative Site, Bucharest

030303

RECRUITING

Investigative Site, Bucharest

08036

RECRUITING

Investigative Site, Barcelona

E1 1FR

RECRUITING

Investigative Site, London

SE5 9NU

RECRUITING

Investigative Site, London

NG7 2UH

RECRUITING

Investigative Site, Nottingham

All Listed Sponsors

lead

Vir Biotechnology, Inc.

INDUSTRY